1,993
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is <130/80 mmHg the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?

, &

References

  • Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–610.
  • Williams B, Mancia G, Spiering W, Authors/Task Force Members, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.
  • Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–1324.
  • Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004.
  • American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S125–S150.
  • Olsen E, Holzhauer B, Julius S, et al. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. Blood Press. 2021;30:1–8.
  • Olsen E, Holzhauer B, Julius S, et al. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Press. 2021;30:1–8.
  • Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50(2):299–305.
  • Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37(12):955–964.
  • Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585.
  • Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35(5):922–944.
  • Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–615.
  • Whelton PK, Pollock BD. Is it time to employ a measure of visit-to-visit variability in clinical practice? Hypertension. 2017;70(2):227–228.
  • Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124–1140.
  • Lebeau JP, Biogeau J, Carre M, et al. Consensus study to define appropriate inaction and inappropriate inertia in the management of patients with hypertension in primary care. BMJ Open. 2018;8(7):e020599
  • Pallares-Carratala V, Bonig-Trigueros I, Palazon-Bru A, et al. Clinical inertia in hypertension: a new holistic and practical concept within the cardiovascular continuum and clinical care process. Blood Press. 2019;28(4):217–228.
  • Konig M, Gollasch M, Rosada A, et al. Antihypertensive treatment patterns and blood pressure control in older adults: results from the Berlin Aging Study II. Drugs Aging. 2018;35(11):993–1003.
  • Kjeldsen SE, Julius S, Dahlof B, et al. Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial Lecture. Blood Press. 2015;24(1):1–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.